Navigation Links
Chicken-Pox vaccine not fool proof

For over five years, doctors in India have been recommending chicken pox vaccination for children, even though it does not figure in the list of mandatory //vaccinations, and no comparative study has ever been conducted.

Now they may have to do a rethink, after new studies in the US have raised doubts about its effectiveness. According to the study, published last week in The Journal of the American Medical Association, found the effectiveness of the vaccine is found to fade substantially a year after it is administered.

In children below 15 months, the vaccine appears to have less immunity. Experts are now questioning whether the vaccine — for long a topic of debate in the US — should be used at all, as immunisation just pushes the disease into adulthood when it could take a more severe form.

Adults whose childhood immunity has worn off could be in trouble later age as it increases their vulnerability to the disease, say experts. ‘‘The findings do raise some pertinent questions. It is a matter of concern.’’ says Dr Anupal Sibal, senior child specialist, Indraprastha Apollo Hospitals.

The study, carried out over several years by researchers at Yale Medical School, further found that in children above 15 months, protection was 99 per cent in the first year, and only 73 per cent in those below 15 months. However, those who got chicken pox after receiving the shots had only mild symptoms.

What’s the solution for this then? Sibal suggests administering a second dose, "Even now, children beyond 15 years are recommended two doses." The catch: it’s very expensive.br>

'"/>




Page: 1

Related medicine news :

1. New hope for cancer victims – will vaccine cure the deadly bug
2. New vaccine helps allergy and asthma patients
3. Man against HIV – new vaccine ready for human trials
4. New vaccine helps allergy and asthma patients
5. Development of AIDS vaccine -- Chiron Corp in talks with four Indian cos
6. HIV did not arise from polio vaccine
7. Double impact vaccine
8. High Demand for a child vaccine
9. A new vaccine for leukemia
10. Shortage of MMR vaccine
11. Anthrax vaccine produced
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/28/2017)... ... March 28, 2017 , ... Medforce Technologies, Inc., ... to announce it has joined the National Association for Home Care and Hospice ... ill, disabled, and dying Americans of all ages and the caregiver who provide ...
(Date:3/28/2017)... ... March 28, 2017 , ... Alert Sentry Group LLC., ... (Mobile Personal Emergency Response Systems), the iSAFE and the iSAFE Plus. These iSAFE products ... first of their kind, the iSAFE and iSAFE Plus offer direct GPS Location and ...
(Date:3/28/2017)... ... March 28, 2017 , ... Usually, the impending arrival ... wardrobe. However, for those self-conscious about a double chin, this means more anxiety than ... solution. , “For most people, a double chin is undesirable,” Dr. Goldman said, ...
(Date:3/28/2017)... (PRWEB) , ... March 28, 2017 , ... ... leading physicians, Paul Yost, will begin serving as new board chair for Orange ... month. Yost will serve the remainder of soon-to-be former chair Mark Refowitz’s term, ...
(Date:3/28/2017)... ... , ... With less than 10,000 dermatologists in the United States and more ... while the desire to conquer breakouts and eliminate skincare stress is widespread. Curology ... today released its inaugural survey on the State of Acne in America. , ...
Breaking Medicine News(10 mins):
(Date:3/28/2017)... , March 28, 2017 The ... reach USD 8.0 billion by 2025, according to a ... incidence of infectious diseases and cancer is expected to ... disease diagnosis over the coming years. In addition, higher ... autologous and allogenic stem cell therapy, due to adverse ...
(Date:3/27/2017)... 27, 2017 Summary This ... Bayer and its partnering interests and activities since 2010. ... an in-depth insight into the partnering activity of one of ... company reports are prepared upon purchase to ensure inclusion of ... The report will be delivered in PDF format within ...
(Date:3/27/2017)... , March 27, 2017  ImMAGE Biotherapeutics (OTCMKTS: IMMG), ... successfully passed early toxicology and efficacy studies. The company ... target a specific protein, MAGE A, in an effort ... cancer. After 4 weeks of treatment ... show very little toxicity in a full toxicology report ...
Breaking Medicine Technology: